Risk factors for hepatocellular carcinoma in Japanese patients with autoimmune hepatitis type 1

Journal of Gastroenterology

Volumn 47, Issue 5, 2012, Pages 569-576

  Hino Arinaga, Teruko ^a   Ide, Tatsuya ^a   Kuromatsu, Ryoko ^a   Miyajima, Ichiro ^a   Ogata, Kei ^a   Kuwahara, Reiichiro ^a   Hisamochi, Akiko ^a   Torimura, Takuji ^a   Sata, Michio ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Autoimmune hepatitis; Hepatocellular carcinoma; Liver cirrhosis; Risk factors

Indexed keywords

ALANINE AMINOTRANSFERASE; AZATHIOPRINE; PREDNISOLONE; URSODEOXYCHOLIC ACID;

ADULT; ARTICLE; AUTOIMMUNE HEPATITIS; CANCER INCIDENCE; CANCER RISK; CANCER STAGING; COMBINATION CHEMOTHERAPY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG DOSE REDUCTION; ECHOGRAPHY; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; JAPANESE; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RELAPSE; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR;

AGED; ALANINE TRANSAMINASE; AZATHIOPRINE; BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; CHOLAGOGUES AND CHOLERETICS; DRUG THERAPY, COMBINATION; FEMALE; GLUCOCORTICOIDS; HEPATITIS, AUTOIMMUNE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; JAPAN; KAPLAN-MEIER ESTIMATE; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PREDNISOLONE; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME; URSODEOXYCHOLIC ACID;

EID: 84865122355     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-011-0519-2     Document Type: Article

References (46)

1. Roberts SK, Therneau TM, Czaja AJ. Prognosis of histological cirrhosis in type 1 autoimmune hepatitis. Gastroenterology. 1996;110:848-57. (Pubitemid 26071852)
2. Toda G, Zeniya M, Watanabe F, Imawari M, Kiyosawa K, Nishioka M, et al. Present status of autoimmune hepatitis in Japan-correlating the characteristics with international criteria in an area with a high rate of HCV infection. Japanese National Study Group of Autoimmune Hepatitis. J Hapetol. 1997;26: 1207-12. (Pubitemid 27346631)
3. Czaja AJ. Treatment of autoimmune hepatitis. Semin Liver Dis. 2002;22:365-78.
4. Hino T, Kumashiro R, Ide T, Koga Y, Ishii K, Tanaka E, et al. Predictive factors for remission and death in 73 patients with autoimmune hepatitis in Japan. Int J Mol Med. 2003;11:749-55.
5. Wang KK, Czaja AJ. Hepatocellular carcinoma in corticosteroid-treated severe autoimmune chronic active hepatitis. Hepatology. 1988;8:1679-83. (Pubitemid 19021908)
6. Yousuf M, Kiyosawa K, Sodeyama T, Yoda H, Nakano Y, Furuta S. Development of hepatocellular carcinoma in a man with autoimmune chronic active hepatitis. J Gastroenterol Hepatol. 1992;7:66-9.
7. Ryder SD, Koskinas J, Rizzi PM, McFarlane IG, Portmann BC, Naoumov NV, et al. Hepatocellular carcinoma complicating autoimmune hepatitis: role of hepatitis C virus. Hepatology. 1995;22:718-22.
8. Park SZ, Nagorney DM, Czaja AZ. Hepatocellular carcinoma in autoimmune hepatitis. Dig Dis Sci. 2000;45:1944-8.
9. Nishiyama R, Kanai T, Abe J, Hara R, Watahiki Y, Sakaguchi T, et al. Hepatocellular carcinoma associated with autoimmune hepatitis. J Hepatobiliary Pancreat Surg. 2004;11:215-9. (Pubitemid 38996949)
10. Okino H, Satoh T, Watanabe J, Masumoto A, Takeda S. Hepa-tocellular carcinoma arising from autoimmune hepatitis: report of a case. Surg Today. 2007;37:716-8. (Pubitemid 47101265)
11. Yeoman AD, Al-Chalabi T, Karani JB, Quaglia A, Devlin J, Mieli-Vergani G, et al. Evaluation of risk factors in the development of hepatocellular carcinoma in autoimmune hepatitis: implications for follow-up and screening. Hepatology. 2008;48: 863-70.
12. Montano-Loza AJ, Carpenter HA, Czaja AJ. Predictive factors for hepatocellular carcinoma in type 1 autoimmune hepatitis. Am J Gastroenterol. 2008;103:1944-51.
13. Werner M, Almer S, Prytz H, Lindgren S, Wallerstedt S, Björnsson E, et al. Hepatic and extrahepatic malignancies in autoimmune hepatitis. A long-term follow-up in 473 Swedish patients. J Hepatol. 2009;50:388-93.
14. Teufel A, Weinmann A, Centner C, Piendl A, Lohse AW, Galle PR, et al. Hepatocellular carcinoma in patients with autoimmune hepatitis. World J Gastroenterol. 2009;15:578-82.
15. Johnson P, McFarlane I. Meeting report: International Autoimmune Hepatitis Group. Hepatology. 1993;18:993-1005.
16. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults. N Engl J Med. 2003;348:1625-38. (Pubitemid 36459468)
17. El-Serag HB, Richardson PA, Everhart JE. The role of diabetes in hepatocellular carcinoma: a case-control study among United States Veterans. Am J Gastroenterol. 2001;96:2462-7. (Pubitemid 32769212)
18. Regimbeau JM, Colombat M, Mognol P, Durand F, Abdalla E, Degott C, et al. Obesity and diabetes as a risk factor for hepa-tocellular carcinoma. Liver Transpl. 2004;10:S69-73. (Pubitemid 38240104)
19. Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB. Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut. 2005;54:533-9. (Pubitemid 40403031)
20. Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P, et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology. 2002;123:134-40. (Pubitemid 34747534)
21. Marrero JA, Fontana RJ, Su GL, Conjeevaram HS, Emick DM, Lok AS. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology. 2002;36:1349-54. (Pubitemid 35403524)
22. Mori S, Yamasaki T, Sakaida I, Takami T, Sakaguchi E, Kimura T, et al. Hepatocellular carcinoma with nonalcoholic steatohep-atitis. J Gastroenterol. 2004;39:391-6.
23. Polesel J, Zucchetto A, Montella M, Dal Maso L, Crispo A, La Vecchia C, et al. The impact of obesity and diabetes mellitus on the risk of hepatocellular carcinoma. Ann Oncol. 2009;20:353-7.
24. Gao C, Yao SK. Diabetes mellitus: a "true" independent risk factor for hepatocellular carcinoma? Hepatobiliary Pancreat Dis Int. 2009;8:465-73.
25. Alvarez F, Berg PA, Bianchi FB, Bianchi L, Burroughs AK, Cancado EL, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol. 1999;31:929-38. (Pubitemid 29514229)
26. Kuzuya T, Nakagawa S, Satoh J, Kanazawa Y, Iwamoto Y, Kobayashi M, et al. Committee of the Japan Diabetes Society on the diagnostic criteria of diabetes mellitus. Report of the committee on the classification and diagnostic criteria of diabetes mellitus. Diabetes Res Clin Pract. 2002;55:65-85. (Pubitemid 34036538)
27. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology. 1994;19:1513-20. (Pubitemid 24166476)
28. Group formed to establish the guidelines for evidence-based clinical practice for the treatment of liver cancer. Clinical practice guidelines for hepatocellular carcinoma. Tokyo: Kanehara & Co.; 2005.
29. Kudo M, Okanoue T. Management of hepatocellular carcinoma in Japan: consensus-based clinical practice manual proposed by the Japan Society of Hepatology. Oncology. 2007;72:S2-15.
30. Jones M, Symmons D, Finn J, Wolfe F. Does exposure to immunosuppressive therapy increase the 10 years malignancy and mortality risks in rheumatoid arthritis? A matched cohort study. Br J Rheumatol. 1996;35:738-45.
31. Asten P, Barrett J, Symmons D. Risk of developing certain malignancies is related to duration of immunosuppressive drug exposure in patients with rheumatic diseases. J Rheumatol. 1999;26:1705-14. (Pubitemid 29367309)
32. Bernatsky S, Clarke AE, Suissa S. Hematologic malignant neoplasms after drug exposure in rheumatoid arthritis. Arch Intern Med. 2008;168:378-81. (Pubitemid 351347129)
33. Baecklund E, Iliadou A, Askling J, Ekbom A, Backlin C, Granath F, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum. 2006;54:692-701.
34. Miyake Y, Iwasaki Y, Terada R, Okamoto R, Ikeda H, Makino Y, et al. Persistent elevation of serum alanine aminotransferase levels leads to poor survival and hepatocellular carcinoma development in type 1 autoimmune hepatitis. Aliment Pharmacol Ther. 2006;24:1197-205. (Pubitemid 44427507)
35. Manns MP, Czaja AJ, Gorham JD, Krawitt EL, Mieli-Vergani G, Vergani D, et al. American Association for the Study of Liver Diseases. Diagnosis and management of autoimmune hepatitis. Hepatology. 2010;51:2193-213.
36. Czaja A, Freese D. Diagnosis and treatment of autoimmune hepatitis. Hepatology. 2002;36:479-97. (Pubitemid 34810370)
37. Lamers MM, van Oijen MG, Pronk M, Drenth JP. Treatment options for autoimmune hepatitis: a systematic review of randomized controlled trials. J Hepatol. 2010;53:191-8.
38. Miyake Y, Iwasaki Y, Kobashi H, Yasunaka T, Ikeda F, Takaki A, et al. Efficacy of ursodeoxycholic acid for Japanese patients with autoimmune hepatitis. Hepatol Int. 2009;3:556-62.
39. Nakamura K, Yoneda M, Yokohama S, Tomori K, Sato Y, Aso K, et al. Efficacy of ursodeoxycholic acid in Japanese patients with type 1 autoimmune hepatitis. J Gastroenterol Hepatol. 1998;13:490-5.
40. Miyake T, Miyaoka H, Abe M, Furukawa S, Shigematsu S, Furukawa E, et al. Clinical characteristics of autoimmune hepatitis in older aged patients. Hepatol Res. 2006;36:139-42. (Pubitemid 44480644)
41. Umemura T, Ichijo T, Yoshizawa K, Tanaka E, Kiyosawa K. Epidemiology of hepatocellular carcinoma in Japan. J Gastroen-terol. 2009;44:102-7.
42. Tazawa J, Maeda M, Nakagawa M, Ohbayashi H, Kusano F, Yamane M, et al. Diabetes mellitus may be associated with hepatocarcinogenesis in patients with chronic hepatitis C. Dig Dis Sci. 2002;47:710-5. (Pubitemid 34286861)
43. Veldt BJ, Chen W, Heathcote EJ, Wedemeyer H, Reichen J, Hofmann WP, et al. Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus. Hepatology. 2008;47:1856-62. (Pubitemid 351945553)
44. Torisu Y, Ikeda K, Kobayashi M, Hosaka T, Sezaki H, Akuta N, et al. Diabetes mellitus increases the risk of hepatocarcinogenesis in patients with alcoholic cirrhosis: a preliminary report. Hepatol Res. 2007;37:517-23. (Pubitemid 46864247)
45. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenter-ology. 2004;127:S35-50. (Pubitemid 39423368)
46. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132: 2557-76. (Pubitemid 46890874)